ARRY vs AVGO

ARRY's deterministic health scores signal significant distress: the Piotroski F-Score of 2/9 indicates poor financial health, with weak profitability, declining revenue, and high leverage. The absence of an Altman Z-Score raises concern, as the Debt/Equity ratio of 2.94 and negative ROE (-19.02%) suggest elevated bankruptcy risk. Despite a modest Price/Sales of 0.82 and a forward P/E of 7.86, the company's -17.9% YoY revenue decline and negative profit margins undermine valuation appeal. Analysts recommend 'buy' with a $10.07 target, but this optimism appears disconnected from deteriorating fundamentals. The 52-week price range ($3.76–$12.23) and recent 1M drop of 37.6% reflect high volatility and weak market confidence.

Broadcom exhibits a dichotomy between elite operational performance and poor deterministic value metrics. While the Piotroski F-Score of 4/9 indicates stable health, the stock trades at a massive premium to its Graham Number ($44.08) and Intrinsic Value ($151.04). This valuation gap is partially justified by a very attractive PEG ratio (0.68) and strong forward P/E (19.65), suggesting high growth expectations. However, aggressive insider selling by the CEO and CFO, combined with a bearish technical trend, offsets the strong analyst 'strong_buy' consensus.